Stock Ratings / Health Care / NGNE / insiders

STTK (29) EVO (47) DRUG (46) PBYI (70) ⌘ Pro Terminal →

Neurogene Inc. (NGNE) Insider, 13F Hedge Fund & Politician Buy/Sell Thermometer

$27.55 -4.41% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $27.28

Neurogene Inc. (NGNE) carries a Roarable Rating of D- (Sell) with 36/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (36/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE D- • RED ALERT Cap $551.3M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on NGNE Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is NGNE stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-03, Neurogene Inc. (NASDAQ: NGNE) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 36/100 at a spot price of $27.55 (-4.41% 1D, market cap $551.3M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 7/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 5/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, NGNE ranks #565 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does NGNE compare to STTK and EVO in the Health Care sector?

▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), NGNE carries a Roarable D- (36/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, STTK (Shattuck Labs Inc.) holds a E grade (29/100 RQD, P/E N/A, ROIC -35.0%, cap $558.0M) and EVO (Evotec SE) posts a D grade (47/100 RQD, P/E N/A, ROIC —, cap $544.3M). Among the 5-stock peer group, PBYI leads on earnings multiple (17.5x) while PBYI leads on capital efficiency (29.3% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for NGNE?

▼

Per NGNE's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001404644), Neurogene Inc. generated $0 in revenue (-100.0% YoY), -$90.4M in net income, and -$78.4M in free cash flow against $288.6M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $27.28 (-0.98%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 8/20 (D-) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (36/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-8.3% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • D-

2-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D

Each axis scored 0–20

12M PRICE TARGET CONE-9.9% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for NGNE)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (36/100 Composite)

🔍 WHY NGNE SCORES 36/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: SEC 10-K Forensic Risk+13/20 pts (36% of score)

Altman Z-Score 12.76 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 2/9

▲ #2 Bullish Driver: Cash Engine Quality+8/20 pts (22% of score)

SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 52% Gross Margin

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade E$21.56+17.8% Next Q

Q2 (-2Q)

Grade E$25.40+6.3% Next Q

Q3 (-1Q)

Grade E$26.99+2.1% Next Q

Current

Grade D-$27.55-8.3% Hist 90D α

Trajectory: E (28) → D- (36)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a NGNE Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While NGNE currently carries a cautious 36/100 (D-) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($30.30) and Max Pain ($28.93) forces dealer call-delta covering toward $45.84.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $NGNE• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “NGNE Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 36%NO 64%Trade / Inspect Odds →

SEC FORM 4 × 13F HEDGE FUNDS × CONGRESSIONAL STOCK ACT

NGNE Smart-Money Thermometer: NET EXECUTIVE TRIMMING / PROFIT-TAKING

Explore All 13F & Congress Whales →

▲ Disclosed Buys: 0 ($0)▼ Disclosed Sales: 0 ($0)

Wide-Open SEC Form 4, 13F & Congressional Disclosure Ledger (NGNE)

No recent open-market Form 4 cluster sales or emergency dumps flagged on NGNE. Visit the Global 13F & Congressional Whale Ledger for cross-market smart-money filings.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring NGNE)

✓Walkthrough of NGNE's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

NGNE // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -2.37%▼ DESCENDING CHANNEL

2026-11-03O $28.82H $28.82L $27.55C $27.55VOL 249.1K

RES: $39.56SUP: $18.15SMA50: $30.30SMA200: $27.92

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

NGNE Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 NGNE Butterfly Map → + Track NGNE →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on NGNE today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for NGNE. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for NGNE today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (NGNE)

Health Care Rank #565 of 1016 ⚔️ STTK vs NGNE Full Matrix →

1. Head-to-Head Health Care Peer Comparison (NGNE vs. STTK, EVO, DRUG, PBYI)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Neurogene Inc. (NGNE) ranks #565 by composite RQD confidence (36/100, grade D-) and #426 by equity capitalization ($551.3M). Within this direct 5-issuer industry benchmark cohort, PBYI leads on earnings valuation at 17.5x trailing P/E, while PBYI leads on capital efficiency and profitability with 29.3% ROIC and 74.5% gross margin. PBYI currently holds the highest overall quantitative score in the immediate peer group at 70/100 (B-) compared with NGNE at 36/100 (D-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
NGNE ACTIVE Neurogene Inc.	D-	36/100	—	—	-35.0%	-4.41%	$551.3M	Benchmark Subject
STTK Shattuck Labs Inc.	E	29/100	—	—	-35.0%	-2.80%	$558.0M	/sttk-vs-ngne →
EVO Evotec SE	D	47/100	—	—	—	-3.16%	$544.3M	/evo-vs-ngne →
DRUG Bright Minds Biosciences Inc.	D	46/100	—	—	—	-3.02%	$539.9M	/drug-vs-ngne →
PBYI Puma Biotechnology Inc	B-	70/100	17.5x	74.5%	29.3%	-0.95%	$538.9M	/pbyi-vs-ngne →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001404644

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Neurogene Inc. (NGNE) reported GAAP revenue of $0 (-100.0% vs. FY2024 revenue of $925.0K ) , GAAP net income of -$90.4M, operating cash flow of -$77.2M, and free cash flow of -$78.4M (-9.7% YoY). On the balance sheet, NGNE closed FY2025 with $288.6M in total assets against $0 in total debt (Altman Z-Score: 12.76, Piotroski F-Score: 2/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$0	-$90.4M	-$77.2M	-$78.4M	$288.6M	—
FY2024 (FY)	2024-12-31	$925.0K	-$75.1M	-$70.6M	-$71.4M	$335.7M	—
FY2023 (FY)	2023-12-31	$0	-$36.3M	-$51.4M	-$51.4M	—	—

3. NGNE Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is NGNE stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does NGNE compare to STTK and EVO in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for NGNE?

Where is NGNE trading relative to its 50-day, 200-day, and 52-week technical levels?

NGNE last traded at $27.55 (-4.41% on volume of 249,057 shares), positioning the stock -9.08% below its 50-day simple moving average ($30.30) and -1.33% below its 200-day simple moving average ($27.92). Across its 52-week range of $15.93 to $43.66, NGNE sits at the 41.9% percentile with a 14-day RSI of 50.6 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($24.11 to $30.99).

NGNE Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Are NGNE insiders and hedge funds buying or selling?

Roarable's SEC Form 4 and 13F Whale Thermometer currently classifies NGNE leadership and institutional positioning as: NET EXECUTIVE TRIMMING / PROFIT-TAKING.

Direct Sub-Reports: NGNE RQD Cockpit NGNE 12M Forecast NGNE Earnings & Move NGNE Dividends & DRIP NGNE Insiders & 13F NGNE Whale Options NGNE Profit Sankey NGNE News & Why

ROARABLE RATING BRIEF • RQD 36/100 (D-) ✓ STAGE-C NUMBER FIREWALL VERIFIED

NGNE — Neurogene Inc.: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5

As of: 2026-11-02T15:34:51Z

Roarable Rating Brief: What This Means to a Prospective Investor

The Roarable RQD rating is 44, a letter grade of D, with the verdict "Roarable Sell — Underperform / Distribution Warning," per the Roarable RQD rating. The five pillars are scored as follows: Fundamental Cash Engine 8/20 (ROIC -35%; FCF yield -13.59%), Whale 13F Flow 10/20 (institutional accumulation and options positioning), Insider Conviction 3/20 (SEC Form 4 and Congressional PTR cluster flow), Macro Regime Fit 10/20 (beta 1.0; sector sensitivity), and Forensic Balance Sheet 13/20 (Altman Z 12.76; Piotroski F 2/9; Debt/Equity 0.5), all per the Roarable RQD rating.

For a prospective investor, the weakest pillar is insider conviction (3/20), and the cash engine pillar (8/20) reflects the negative ROIC and negative free cash flow yield. The balance sheet pillar (13/20) is the strongest, supported by the reported Altman Z-Score and Debt/Equity ratio, though the Piotroski F-Score of 2/9 is weak. Upside drivers would need to come from improved cash generation or a change in the insider and flow signals; the source data does not describe a specific valuation tradeoff beyond the metrics listed here. The rating is a factual summary of the data provided, not a recommendation.

Financial Trend

Period	Revenue	Operating Income	Net Income	EPS	FCF	Cash	Debt
FY 2025	$0.0M	$-103.3M	$-90.4M	N/A	$-78.4M	$103.8M	N/A
FY 2024	$0.9M	$-82.6M	$-75.1M	N/A	$-71.4M	$136.6M	N/A
FY 2023	$0.0M	$-55.6M	$-36.3M	N/A	$-51.4M	N/A	N/A

Per the SEC financials, margins are reported as 0% for gross, operating, and net margin in the market data, and ROIC is -35%. The Altman Z-Score is 12.76 and the Piotroski F-Score is 2/9, both per the Roarable RQD rating's forensic balance sheet pillar. The Debt/Equity ratio is 0.5 per the same source. Reported cash declined from $136.6M in FY 2024 to $103.8M in FY 2025 per the SEC financials.

Recent Catalysts & News Wire Analysis

Per the recent news feed, the headlines include a J.P. Morgan rating note described as an Overweight rating, an Inducement Grants announcement under Nasdaq Listing Rule 5635(c)(4), a passive investor report of 2.23 million shares, a Prudential Financial position report of 2.23 million shares, an HC Wainwright reiteration of a Buy rating with a $65 price target, and a MarketBeat institutional ownership item. All items are tagged MARKET WIRE and carry a YELLOW light. The Butterfly Supply-Chain Graph reports no supply-chain links and no proprietary signals. Risk watch items drawn from the financials include continued operating losses and negative free cash flow across the reported periods.

Analyst View & Smart Money Ownership

Analyst data is NONE per the source. Consensus rating and price targets are Not available in source data beyond the HC Wainwright Buy reiteration with a $65 price target cited in the news feed. Holder data is NONE; SEC Form 4 insider, 13F, and Congressional trade details are Not available in source data, though the Roarable RQD pillars reference institutional accumulation and insider cluster flow.

Open Questions

What are the company's products, revenue sources, and customers, given that reported revenue is $0.0M in FY 2025?
What are the reported EPS, debt balances, and P/E ratios, since these fields are N/A or unavailable?
What is the composition and timing of the 2.23 million share institutional positions and the insider cluster flow referenced in the RQD rating?
What is the company's cash runway given reported cash of $103.8M against FY 2025 free cash flow of $-78.4M?
What are the clinical or regulatory catalysts underlying the J.P. Morgan and HC Wainwright ratings?

NGNE Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Neurogene Inc. (NGNE) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to NGNE Debate Forum (3) ↓

🟡 MARKET WIRE Seeking Alpha • 16h ago

Neurogene stock a new Overweight at J.P. Morgan (NGNE:NASDAQ)

Seeking Alpha report covering Neurogene Inc. (NGNE) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance • 19h ago

Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Yahoo Finance report covering Neurogene Inc. (NGNE) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Stock Titan • 22h ago

A passive investor reports 2.23 million shares of Neurogene (NGNE).

Stock Titan report covering Neurogene Inc. (NGNE) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE GuruFocus • 1d ago

Prudential Financial Inc. Opens New Position in Neurogene Inc. (NGNE) With 2.23 Million Share Purchase

GuruFocus report covering Neurogene Inc. (NGNE) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE TradingView • 1d ago

HC Wainwright & Co. reiterates Buy rating on Neurogene, $65 price target

TradingView report covering Neurogene Inc. (NGNE) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE MarketBeat • 1d ago

Neurogene (NGNE) Institutional Ownership 2026

MarketBeat report covering Neurogene Inc. (NGNE) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Stock Titan • 1d ago

Prudential reports a passive Neurogene (NGNE) stake spanning more than 2 million shares.

Stock Titan report covering Neurogene Inc. (NGNE) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE MarketBeat • 1d ago

Neurogene (NGNE) Short Interest & Short Float | Updated Nov 2026

MarketBeat report covering Neurogene Inc. (NGNE) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

NGNE Bull vs. Bear Conversation Board — What's Your Call at $27.55?

🐂 33% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON NGNE 🐻 67% BEARISH CONVICTION

RO RoarDesk_Moderator Roarable Research Desk 🐻 BEARISH 🎯 Target: $25.36 (-12.0%)

📌 Pinned Debate

🔥 Official Bull vs. Bear Debate: Is NGNE (D • RQD 44/100) a Buy at $28.82?

Welcome to the NGNE (Neurogene Inc.) Roar Pit. Current RQD Composite is 44/100 (Roarable Sell — Underperform / Distribution Warning) in Biotechnology: Pharmaceutical Preparations. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.

SK SkepticalCFA Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $22.48 (-22.0%)

Spot @ $28.82

Pump the brakes on NGNE — check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on NGNE, but look at what you are paying: current EV/EBITDA multiples with tightening sector spreads. Unless Neurogene Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

TA TapeReader_Pro Verified K Arena Trader 🐂 BULLISH 🎯 Target: $33.14 (+15.0%)

Spot @ $28.82

NGNE cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on NGNE, the market is fixating on short-term headline noise in Biotechnology: Pharmaceutical Preparations and ignoring the balance sheet and cash flow trajectory. At $28.82 (52-wk range $15.93 - $43.66), any beat on forward guidance forces shorts and underweight funds to chase.